Biktarvy

DRUG11 trials

Conditions

ARTBIC/FTC/TAFBone Diseases, MetabolicBuprenorphine DependenceCo-infectionCoronary Artery DiseaseHCV CoinfectionHIV

Phase 3

Effects of Biktarvy on CFR in Stable HIV Patients

CompletedNCT03656783

Brigham and Women's HospitalHIV

Start: 2018-09-14End: 2021-09-15Updated: 2023-02-08

The Late Presenter Treatment Optimisation Study

CompletedNCT03696160

NEAT ID FoundationHIV/AIDS

Start: 2019-03-05End: 2024-06-17Updated: 2025-12-17

A Test and Treat Strategy in New HIV Diagnosis.

CompletedNCT04416906

Judit Pich MartínezHIV-1-infection

Start: 2020-10-05End: 2023-05-11Updated: 2023-09-18

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

CompletedNCT04653194

Chelsea and Westminster NHS Foundation TrustHuman Immunodeficiency Virus

Start: 2020-09-30End: 2023-07-31Updated: 2024-02-08

Phase 4

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

NCT03549312

Saskatchewan Health Authority - Regina AreaBone Diseases, Metabolic, Buprenorphine Dependence, Co-infection +6

Start: 2018-02-01End: 2021-06-22Target: 25Updated: 2019-12-24

How Does Antiretroviral Therapy Affect Coronary Atherosclerosis: a Serial CT Study

WithdrawnNCT03986697

University of LiverpoolCoronary Artery Disease, Hiv

Start: 2020-02-04End: 2021-03-29Updated: 2024-12-18

Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM

CompletedNCT04039217

Emory UniversityART, HIV

Start: 2019-09-30End: 2020-08-28Updated: 2022-02-22

Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens

CompletedNCT04860505

Emory UniversitySexually Transmitted Diseases

Start: 2021-05-20End: 2022-05-09Updated: 2023-05-23

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

NCT05463783

East Carolina UniversityHIV Infections, Obesity

Start: 2023-03-14End: 2025-03-31Target: 30Updated: 2023-11-14

Unknown Phase

Antiretroviral Speed Access Program

RecruitingNCT04897243

Dr. Bertrand LeboucheHIV Infection

Start: 2019-08-01End: 2024-12-31Target: 75Updated: 2024-02-21

Real World Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide(BIC/FTC/TAF) in PLWH in Precarity Settings in France -IMEA073

Not yet recruitingNCT07122557

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'BaBIC/FTC/TAF, HIV-1, Low Income Population +1

Start: 2025-09-30End: 2025-12-31Target: 320Updated: 2025-08-14

Related Papers

Chelating anticoagulants reduce plasma doxycycline measurements: implications for doxy PEP monitoring.

2026-02-17

Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial.

2025-12-01

Evaluation of the effect of 48 weeks of BIC/F/TAF and DRV/c/F/TAF on platelet function in the context of rapid ART start

HIV Research & Clinical Practice2025-01-07

Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study

Journal of Antimicrobial Chemotherapy2024-07-242 citations

Pharmacokinetics of single dose doxycycline in the rectum, vagina, and urethra: implications for prevention of bacterial sexually transmitted infections.

2024-02-2925 citations

Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy

Journal of the American Heart Association2023-11-108 citations